Cinclus Pharma Holding AB (publ)

OM:CINPHA Stock Report

Market Cap: SEK 521.2m

Cinclus Pharma Holding Management

Management criteria checks 1/4

Cinclus Pharma Holding's CEO is Christer Ahlberg, appointed in Jan 2021, has a tenure of 5.42 years. total yearly compensation is SEK7.12M, comprised of 59.1% salary and 40.9% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth SEK1.17M. The average tenure of the management team and the board of directors is 3.4 years and 2.9 years respectively.

Key information

Christer Ahlberg

Chief executive officer

SEK 7.1m

Total compensation

CEO salary percentage59.13%
CEO tenure5.4yrs
CEO ownership0.2%
Management average tenure3.4yrs
Board average tenure2.9yrs

Recent management updates

Recent updates

Narrative Update • Jun 05

CINPHA: Phase III GERD Progress Will Drive Future Upside Potential

Analysts now set a price target of SEK46.25 for Cinclus Pharma Holding, down from SEK53.33. This reflects updated assumptions for faster revenue growth of 19.07%, a slightly higher profit margin of 20.05% and a lower future P/E of 108.86x.
Narrative Update • May 14

CINPHA: FDA Green Light For Single Pivotal Trial Will Drive Upside

Analysts have adjusted their price target on Cinclus Pharma Holding to SEK53.33 from SEK55, reflecting updates to fair value assumptions, growth expectations, margins and a higher projected future P/E multiple. What's in the News The FDA confirms that a single pivotal study supported by additional evidence will be the new standard for US drug approvals, and Cinclus Pharma's current Phase III program for erosive GERD is described as a sufficient basis for a future US regulatory submission (Key Developments).
Narrative Update • Apr 28

CINPHA: Upcoming Phase III GERD Results Will Drive Future Upside Potential

Analysts have trimmed their price target on Cinclus Pharma Holding to SEK 40 from SEK 50, reflecting updated assumptions for revenue growth, profit margins, discount rate, and future P/E multiples. What's in the News The FDA clarifies that a single adequate and well controlled pivotal study with supportive evidence will be the new standard for US drug approvals, including for common diseases, and confirms Cinclus Pharma's current Phase III program in erosive GERD as a sufficient basis for a US regulatory submission (company announcement).
Narrative Update • Nov 28

CINPHA: FDA Guidance Will Support Pivotal Phase III Trial Momentum

Analysts have adjusted their price target for Cinclus Pharma Holding, keeping it at SEK 55.00 per share. Updated forecasts indicate a more cautious outlook for revenue growth, but there is a slight improvement in expected profit margins.
Narrative Update • Nov 13

CINPHA: Clear FDA Guidance Will Drive Late-Stage Trial Progress

Narrative Update on Cinclus Pharma Holding Analysts have maintained their price target for Cinclus Pharma Holding at SEK 55.00. They noted only minor updates to profit margin and discount rate projections, with no change to their fair value estimate.
Narrative Update • Oct 30

Advancing Late-Stage GERD Studies Will Drive Substantial Long-Term Upside

Analysts have maintained their price target for Cinclus Pharma Holding at SEK 55.00, citing ongoing expectations for strong profit margins and sustained valuation multiples. What's in the News Cinclus Pharma received positive feedback from the U.S. Food and Drug Administration (FDA) on its Chemistry, Manufacturing, and Controls (CMC) strategy.
Narrative Update • Oct 15

PCAB Pipeline Will Revolutionize Severe GERD Treatment Globally

Analysts have revised their price target for Cinclus Pharma Holding downwards from SEK 61.67 to SEK 55.00. This change reflects updated views on revenue growth potential and profit margin projections.
New Narrative • Aug 24

PCAB Pipeline Will Revolutionize Severe GERD Treatment Globally

Key Takeaways Innovative drug formulation, strong market demand, and strategic partnerships position Cinclus Pharma for significant revenue and margin growth in both domestic and international markets. Retention of global commercial rights enables flexible licensing or direct launch strategies, supporting long-term earnings potential through multiple income streams.
Analysis Article • Aug 19

Here's Why We're Not Too Worried About Cinclus Pharma Holding's (STO:CINPHA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Dec 22

Cinclus Pharma Holding (STO:CINPHA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

CEO Compensation Analysis

How has Christer Ahlberg's remuneration changed compared to Cinclus Pharma Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-SEK 239m

Dec 31 2025SEK 7mSEK 4m

-SEK 184m

Sep 30 2025n/an/a

-SEK 177m

Jun 30 2025n/an/a

-SEK 173m

Mar 31 2025n/an/a

-SEK 165m

Dec 31 2024SEK 6mSEK 4m

-SEK 168m

Sep 30 2024n/an/a

-SEK 158m

Jun 30 2024n/an/a

-SEK 183m

Mar 31 2024n/an/a

-SEK 203m

Dec 31 2023SEK 5mSEK 3m

-SEK 215m

Dec 31 2022SEK 5mSEK 4m

-SEK 249m

Dec 31 2021SEK 4mSEK 2m

-SEK 76m

Compensation vs Market: Christer's total compensation ($USD731.53K) is above average for companies of similar size in the Swedish market ($USD306.11K).

Compensation vs Earnings: Christer's compensation has increased whilst the company is unprofitable.

CEO

Christer Ahlberg (55 yo)

5.4yrs
Tenure
SEK 7,116,000
Compensation

Mr. Christer Ahlberg serves as the Chief Executive Officer & President of Cinclus Pharma Holding AB Since 2021. He served as a Director at PMD Device Solutions AB since 2021 until 2024. He served as Direct...

Leadership Team

NamePositionTenureCompensationOwnership
Lennart Hansson
Co-founder & Chairman of the Board12.4yrsSEK 426.00k2.33%
SEK 12.1m
Christer Ahlberg
CEO & President5.4yrsSEK 7.12m0.22%
SEK 1.2m
Peter Unge
Co-founder & Member of Scientific Advisory Boardno dataSEK 1.08m4.49%
SEK 23.4m
Magnus Christensen
Chief Financial Officerless than a yearno datano data
Kajsa Larsson
Chief Medical Officer4.4yrsno data0.035%
SEK 182.8k
Jesper Wiklund
Chief Business Officer3.4yrsno data0.12%
SEK 610.3k
Peter Wallich
Chief Commercial Officer & Commercial Directorno datano datano data
Margit Mahlapuu
Executive R&D Director2.4yrsno datano data
3.4yrs
Average Tenure
58.5yo
Average Age

Experienced Management: CINPHA's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Lennart Hansson
Co-founder & Chairman of the Board12.4yrsSEK 426.00k2.33%
SEK 12.1m
Peter Unge
Co-founder & Member of Scientific Advisory Boardless than a yearSEK 1.08m4.49%
SEK 23.4m
Helena Levander
Independent Director5.4yrsSEK 247.00k0.11%
SEK 563.0k
Wenche Sandsborg
Independent Director10.4yrsSEK 227.00k0.050%
SEK 260.9k
Torbjörn Koivisto
Independent Director9.4yrsSEK 227.00k0.20%
SEK 1.1m
Fredrik Johansson
Directorless than a yearno datano data
Anders Lundstrom
Directorless than a yearno datano data
David Armstrong
Directorless than a yearno datano data
2.9yrs
Average Tenure
69yo
Average Age

Experienced Board: CINPHA's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/25 11:02
End of Day Share Price 2026/06/25 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cinclus Pharma Holding AB (publ) is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ulrik TrattnerDNB Carnegie
Fredrik ThorRedeye
Kevin SuleRedeye